Schizophrenia |
Schizophrenia is a severe psychiatric condition where patients suffer severe symptoms of delusion and paranoia (“positive symptoms”). These are the highly characteristic pathognomic symptoms are quite well treated by current drugs. Patients also suffer from negative symptoms, such as flat personality affect and have cognitive deficits, such as deficits in attention, executive functioning, memory and intelligence, which contribute strongly to functional outcome. Schizophrenia affects approximately 24 million people worldwide, often being diagnosed in late adolescence or early adulthood, and often being a life-long disease. Current drugs have made remarkable progress in treating delusion and paranoia, but are much less effective or ineffective in improving cognition or treating negative symptoms. Treatments to improve cognitive function and treat negative symptoms in schizophrenia are major unmet clinical needs. The worldwide market for anti-psychotic drugs was approximately $21 billion in 2007, a 14% growth over 2006.
Mithridion, Inc. | 505 Science Drive, Suite C | Madison, WI 53511 | (608) 443 2432 |